Education and debate

Why industry should register and disclose results of clinical studies—perspective of a recovering academic

BMJ 2005; 330 doi: 10.1136/bmj.330.7497.959 (Published 21 April 2005)
Cite this as: BMJ 2005;330:959.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jesse A Berlin, senior director, statistical science (jberlin@prdus.jnj.com)1
  1. 1 Johnson & Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560, USA

    Although it's not typical, in a scholarly publication such as the BMJ, to add a personal perspective to a commentary, I believe that in this situation my background is relevant to the discussion. My doctoral dissertation, written in 1988, dealt with the topic of publication bias, which was well described in the Ottawa statement appearing in this issue.1 Since then, I've contributed to several studies of factors affecting publication, including an early empirical demonstration of publication bias.2

    About six months ago, I moved from a university, where I had spent 15 years, to a position in a large pharmaceutical research and development group. Registration and disclosure of the results of clinical studies have, not surprisingly, been topics of numerous conversations where I work.

    At …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular